Synthesis and Cytotoxic Study of a Platinum(IV) Anticancer Prodrug with Selectivity toward Luteinizing Hormone-Releasing Hormone (LHRH) Receptor-Positive Cancer Cells

Inorganic Chemistry
Houzong YaoGuangyu Zhu

Abstract

Platinum drugs including cisplatin are widely used in clinics to treat various types of cancer. However, the lack of cancer-cell selectivity is one of the major problems that lead to side effects in normal tissues. Luteinizing hormone-releasing hormone (LHRH) receptors are overexpressed in many types of cancer cells but rarely presented in normal cells, making LHRH receptor a good candidate for cancer targeting. In this study, we report the synthesis and cytotoxic study of a novel platinum(IV) anticancer prodrug functionalized with LHRH peptide. This LHRH-platinum(IV) conjugate is highly soluble in water and quite stable in a PBS buffer. Cytotoxic study reveals that the prodrug selectively targets LHRH receptor-positive cancer cell lines with the cytotoxicities 5-8 times higher than those in LHRH receptor-negative cell lines. In addition, the introduction of LHRH peptide enhances the cellular accumulation in a manner of receptor-mediated endocytosis. Moreover, the LHRH-platinum(IV) prodrug is proved to kill cancer cells by binding to the genomic DNA, inducing apoptosis, and arresting the cell cycle at the G2/M phase. In summary, we report a novel LHRH-platinum(IV) anticancer prodrug having largely improved selectivity toward LH...Continue Reading

References

Jun 1, 1977·Annals of Internal Medicine·M RozencweigF M Muggia
Mar 22, 1990·The New England Journal of Medicine·L X CubedduA L Finn
Jan 1, 1987·Advances in Enzyme Regulation·K S VitolsF M Huennekens
Jul 17, 1999·European Journal of Endocrinology·A V Schally, A Nagy
Aug 18, 1999·Digestive Surgery·H FriessM W Büchler
Sep 12, 2007·Bioconjugate Chemistry·Sumitra MukhopadhyayStephen J Lippard
Jul 2, 2009·Journal of Controlled Release : Official Journal of the Controlled Release Society·Oleh TaratulaTamara Minko
Jan 5, 2010·Metallomics : Integrated Biometal Science·Ryan C Todd, Stephen J Lippard
Mar 4, 2010·Chemical Communications : Chem Comm·Alina NemirovskiDan Gibson
May 7, 2010·Journal of the American Chemical Society·Wee Han AngStephen J Lippard
Apr 13, 2011·International Journal of Cancer. Journal International Du Cancer·S AggarwalW Hansel
Mar 30, 2013·Cellular Logistics·Dipannita Dutta, Julie G Donaldson
Aug 21, 2013·Molecular Pharmaceutics·Natalia V NukolovaTatiana K Bronich
Nov 6, 2014·Dalton Transactions : an International Journal of Inorganic Chemistry·Anna MassaguerVicente Marchán
Feb 11, 2015·Philosophical Transactions. Series A, Mathematical, Physical, and Engineering Sciences·Timothy C JohnstoneStephen J Lippard
Feb 24, 2016·Dalton Transactions : an International Journal of Inorganic Chemistry·Mauro RaveraDomenico Osella
May 24, 2016·Dalton Transactions : an International Journal of Inorganic Chemistry·Dan Gibson
Jun 3, 2016·Dalton Transactions : an International Journal of Inorganic Chemistry·Qingpeng WangPeng George Wang
Jul 5, 2016·Dalton Transactions : an International Journal of Inorganic Chemistry·Jing MaPeng George Wang
Aug 24, 2017·Chemical Communications : Chem Comm·Nafees MuhammadXiaoyong Wang
Jan 12, 2019·Dalton Transactions : an International Journal of Inorganic Chemistry·Zhigang WangGuangyu Zhu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis